Sie sind auf Seite 1von 1

ajanta pharma limited

Ajanta House,
Charkop, Kandivli (West),
Mumbai 400 067
+91 22 66061000

Deodatta Pandit
Company Secretary
+91 22 66061203

Press Release

Ajanta Pharma posts healthy growth

Net Profit up 56%, Revenue up 35%
Mumbai (July 19, 2012) Ajanta Pharma Limited, a specialty focused pharmaceutical
formulation company, has continued its growth during the first quarter of current
financial year 2012-13. Companys Net Profit grew by 56% at Rs.19.58crs against
Rs.12.53crs for the first quarter last financial year. Revenue for the first quarter of
financial year 2012-13 stood at Rs.174.05crs (Rs.128.80crs), a growth of 35% over the
previous year.
During the quarter, finance cost has seen a major jump at Rs.15.95crs as against
Rs.2.80crs during last year same period. This includes losses on Foreign Currency loans
borrowed by the company. However, the same is set off to major extent through a gain
on foreign currency debtors outstanding, which is included in other income, which has
gone up to Rs.9.76crs against Rs.0.23crs in the previous year same period. This is in line
with the policy followed by the company for natural hedging of its foreign currency
The Companys Board of Directors have fixed the record date of 10th August 2012 for
splitting of its equity share of Rs.10 each in to 2 equity shares of Rs.5 each.
About Ajanta Pharma Limited
Ajanta Pharma is a speciality pharmaceutical formulation company, having leading
brands in the therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many
of the companys products are first of its kind and are leading in their sub therapeutic
segments. Company exports its products to more than 25 countries and established
strong brand equity in these markets. For last 10 years, companys consolidated
performance has been excellent with CAGR of 22% in sales and 46% in net profit.
Ajanta Pharma has its State of the Art R&D centre located at Mumbai, with more than
200 scientists working for formulation development. The company has world class
manufacturing facilities - four located in India and one at Mauritius. One of the
manufacturing facilities at Aurangabad is approved by US FDA, UK MHRA and World health
organisation (WHO), apart from having the approval from FDA of many other countries.
Company is in the process of setting up two more manufacturing facilities in India, one
for regulated markets and another for domestic and rest of the world markets.